CC 122

Drug Profile

CC 122

Alternative Names: CC-122

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Hepatocellular carcinoma
  • Phase I Diffuse large B cell lymphoma; Glioblastoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 01 Sep 2016 Phase-I/II clinical trials in Hepatocellular carcinoma (Combination therapy, Inoperable/Unresectable) in Spain (PO) (NCT02859324)
  • 04 Aug 2016 Celgene Corporation plans a phase I/II trial for Hepatocellular carcinoma (Combination therapy, Inoperable/Unresectable) in USA, Italy, Spain and France (PO) (NCT02859324)
  • 30 Jul 2015 Celgene Corporation plans a phase I trial for Solid tumours (Late-stage disease) and Non-Hodgkin's lymphoma in Japan (NCT02509039)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top